Nxera's Partner Cancer Research UK Presents Data from Successfully Completed Phase 1 Clinical Trial of Cancer Immunotherapy Drug HTL0039732 at ESMO

Core Insights - Nxera Pharma's partner, Cancer Research UK, presented data from the completed Phase 1 part of the Phase 1/2a clinical trial of the immunotherapy drug HTL0039732 at the ESMO 2025 Congress [1][2] - The trial evaluates HTL0039732 as a monotherapy and in combination with atezolizumab in patients with advanced solid tumors resistant to standard therapy [2][5] Clinical Trial Details - The Phase 1 trial involved 13 patients receiving HTL0039732 as a monotherapy and 22 patients receiving it in combination with atezolizumab [2] - The trial's primary objectives were to assess safety and determine the recommended Phase 2 dose (RP2D) [6] - The Phase 2a trial will expand to four cohorts of patients with specific cancer types, including MSS CRC, gastric adenocarcinoma, clear cell renal cell carcinoma, and metastatic castration-resistant prostate cancer [2][3] Safety and Efficacy Results - HTL0039732 was well-tolerated, with no grade 4/5 treatment-related adverse events and no dose-limiting toxicities observed [6] - Grade 3 treatment-related adverse events occurred in 14% of combination patients, comparable to established data for atezolizumab monotherapy [6] - Confirmed partial responses were observed in 50% of ccRCC patients and approximately 9% of MSS-CRC patients, indicating early efficacy [6] Future Development - The recommended Phase 2 dose for the expansion studies is set at 160mg QD in combination with atezolizumab [6] - The trial is being managed by Cancer Research UK's Centre for Drug Development, with recruitment ongoing across multiple sites [3][5] Company Overview - Nxera Pharma is a biopharma company focused on developing innovative medicines to address unmet medical needs globally [10][11] - The company utilizes its NxWave™ platform to advance a pipeline of over 30 active programs targeting various medical areas, including oncology [11][12]